Zydus Wellness (531335) Q4 99/00 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 99/00 earnings summary
3 Nov, 2026Executive summary
FY2000 sales rose to ₹2.60 crore from ₹1.45 crore; the year ended with a pre-tax loss of ₹14.31 lakh, narrowed from ₹45.37 lakh.
Production increased to 377.277 tonnes from 215.241 tonnes, while finished-goods sales volume reached 336,141 kg versus 205,510 kg.
Financial highlights
Total income was ₹2.84 crore versus ₹1.54 crore; total expenditure was ₹2.98 crore versus ₹1.99 crore.
Loss before tax was ₹14.31 lakh, compared with ₹45.37 lakh in FY1999; depreciation was ₹42.74 lakh and interest expense ₹4.21 lakh.
Closing inventory increased to ₹96.44 lakh from ₹48.63 lakh; finished goods were ₹30.79 lakh versus ₹7.45 lakh.
Key financial ratios and metrics
Net fixed assets were ₹2.96 crore versus ₹3.39 crore; net current assets were ₹74.88 lakh versus ₹32.19 lakh.
Secured working-capital bank loans rose to ₹24.05 lakh from ₹14.99 lakh, backed by hypothecation of stock.
Cash and bank balances closed at ₹85,808, compared with ₹42,862 a year earlier.
Latest events from Zydus Wellness
- Sales and EBITDA surged as gross margin expanded and brand growth continued.531335
Q2 26/27 - Sales rose, but FY98 ended with a Rs. 78.8 lakh net loss.531335
Q4 97/98 - Revenue rose 42%, profit after tax doubled, and a Rs. 0.60/share dividend was proposed.531335
Q4 02/03 - Sales surged, but FY99 ended with a Rs 45,36,571 loss before tax.531335
Q4 98/99 - FY02 profit improved as new-product investment positioned the business for growth.531335
Q4 01/02 - Sales more than doubled as profits rose and product expansion broadened.531335
Q4 03/04 - Revenue rose 60.75% as capacity expansion and regional growth plans advanced.531335
Q4 04/05 - Revenue surged 49%, but profit eased amid advertising investment; Nutralite Premium launched.531335
Q4 06/07 - Sales grew 9.12%, profit held near flat, and Cadila Healthcare took a 61.56% stake.531335
Q4 05/06